Skip to main content

World Acceptance Secures $175M Credit Agreement

Tipranks - Sat Oct 4, 2025

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

World Acceptance ( (WRLD) ) has issued an update.

On September 29, 2025, World Acceptance Corporation and its subsidiary, WFC Receivables I, LLC, entered into a Credit Agreement to establish a $175 million revolving warehouse facility. This facility, secured by consumer loan receivables, aims to enhance the company’s financial operations by providing a structured framework for loan management and repayment. The agreement outlines specific terms, including interest rates, payment schedules, and conditions for default, which are designed to maintain financial stability and operational efficiency. The arrangement also allows for the delegation of servicing duties and includes provisions for handling potential servicing or default events, ensuring robust risk management.

The most recent analyst rating on (WRLD) stock is a Buy with a $194.00 price target. To see the full list of analyst forecasts on World Acceptance stock, see the WRLD Stock Forecast page.

Spark’s Take on WRLD Stock

According to Spark, TipRanks’ AI Analyst, WRLD is a Outperform.

World Acceptance’s stock is supported by strong financial performance and positive technical indicators. The company’s robust revenue growth and operational efficiency are key strengths, although high leverage and low net profit margin present risks. The technical analysis suggests bullish momentum, and the valuation indicates reasonable pricing. The positive outlook from the earnings call further supports the stock’s potential, despite some challenges.

To see Spark’s full report on WRLD stock, click here.

More about World Acceptance

Average Trading Volume: 47,978

Technical Sentiment Signal: Buy

Current Market Cap: $923.1M

See more data about WRLD stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.